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Abstract 
Hemagglutinin (HA) is one of the components of botulinum neurotoxin (BoNT) 
complexes and it promotes the absorption of BoNT through the intestinal epithelium by 
at least two specific mechanisms: cell surface attachment by carbohydrate binding, and 
epithelial barrier disruption by E-cadherin binding. It is known that HA forms a three-
arm structure, in which each of three protomers has three carbohydrate-binding sites and 
one E-cadherin-binding site. A three-arm form of HA is considered to bind to these 
ligands simultaneously. In this study, we investigated how the multivalency effect of 
HA influences its barrier-disrupting activity. We prepared type B full-length HA (three-
arm form) and mini-HA, which is a deletion mutant lacking the trimer-forming domain. 
Size-exclusion chromatography analysis showed that mini-HA exists as dimers (two-
arm form) and monomers (one-arm form), which are then separated. We examined the 
multivalency effect of HA on the barrier-disrupting activity, the E-cadherin-binding 
activity, and the attachment activity to the basolateral cell surface. Our results showed 
that HA initially attaches to the basal surface of Caco-2 cells by carbohydrate binding 
and then moves to the lateral cell surface, where the HA acts to disrupt the epithelial 
barrier. Our results demonstrated that the multivalency effect of HA enhances the 
barrier-disrupting activity in Caco-2 cells. We found that the basal cell surface 
attachment and binding ability to immobilized E-cadherin were enhanced by the 
multivalency effect of HA. These results suggest that at least these two factors induced 
by the multivalency effect of HA cause the enhancement of the barrier-disrupting 
activity. 
Keywords 
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Introduction 
    Botulinum neurotoxin (BoNT) is one of the food-poisoning agents and the most 
potent bacterial toxin. BoNTs have been classified serologically into serotype A to G, 
and these toxins cleave soluble N-ethylmaleimide-sensitive factor attachment protein 
receptor (SNARE) proteins in peripheral nerve terminals, resulting in the blocking of  
neurotransmitter release (1). Serotypes A, B, E, and F cause human botulism, whereas 
serotypes C and D mainly cause animal botulism (2). BoNTs are produced as progenitor 
toxin complexes (PTCs) with neurotoxin-associated proteins (NAPs), which include 
non-toxic non-hemagglutinin (NTNHA) and hemagglutinin (HA). The oral toxicity of 
BoNTs is markedly increased in association with NAPs, and the larger forms of PTCs, 
the greater its oral toxicity (3). There are three forms of PTC: M-PTC, L-PTC, and LL-
PTC (also known as 12S toxin, 16S toxin, and 19S toxin, respectively) (3, 4). M-PTC 
consists of BoNT and NTNHA, and L-PTC consists of BoNT, NTNHA, and HA (Fig. 
1a). LL-PTC is assumed to be a dimer of L-PTC (5). When assembled into PTCs, 
NTNHA protects BoNT from an acidic pH and proteolytic enzymes in the 
gastrointestinal tract (6, 7). HA facilitates BoNT absorption across the intestinal 
epithelium by at least two specific mechanisms: the attachment to the luminal surface of 
the intestinal epithelial cells by carbohydrate binding (8–14), and the epithelial barrier 
disruption by E-cadherin binding (15–19). We have proposed an HA-mediated three-
step mechanism for the intestinal absorption of L-PTC (20). In the first step, L-PTC 
binds to glycoproteins/glycolipids at the luminal surface of the intestinal epithelial cells, 
followed by transcytosis. Then, the HA component of L-PTC delivered to the 
basolateral side of epithelial cells directly binds to E-cadherin, which exclusively 
resides on the basolateral surface of epithelial cells, leading to epithelial barrier 
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disruption. Finally, the disruption allows PTCs to pass through the paracellular route 
(20). 
    HA is composed of three subcomponents: HA1, HA2, and HA3 (also known as 
HA33, HA17, and HA70, respectively) (21). Six HA1, three HA2, and three HA3 are 
assembled into a triskelion-shaped hetero-dodecamer in which homo-trimeric HA3 
forms the core of the complex (Fig. 1a,b) (22–25). Hence, the triskelion-shaped HA is a 
trimer of three protomers, composed of two HA1, one HA2, and one HA3, and it has a 
“three-arm” structure (Fig. 1a,b). The carbohydrate-binding activity of HA is 
attributable to HA1 and HA3, which binds to galactose and sialic acid, respectively (9). 
In addition, HA1s of types C and D also bind to sialic acid (10, 26). Triskelion-shaped 
HAs of types A and B have six galactose-binding sites and three sialic acid-binding 
sites (23–25). HAs of types A and B bind to E-cadherin; a region extending over HA2 
and the C-terminal domain of HA3 interacts with E-cadherin ectodomain 1-2 (EC1-2) 
(17–19). Lee, et al. reported that, using isothermal titration calorimetry (ITC), HA (full-
length HA, FL-HA) of type A interacts with E-cadherin EC1-2 expressed in Escherichia 
coli with a dissociation constant (Kd) ~2.3 µM and a 1:3 HA-E-cadherin stoichiometry 
(18). It was also reported that a truncated mutant of HA (termed mini-HA) of type A, 
which lacks the trimer-forming domain of HA3 and represents “one-arm” of the HA, 
interacts with EC1-2 with a Kd ~2.7 µM and a 1:1 HA-E-cadherin stoichiometry (18). 
    Carbohydrate-binding sites and E-cadherin-binding sites are located within each arm 
of HA (Fig. 1c) (18, 19, 24). Therefore, triskelion-shaped HA is capable of exerting 
multivalent binding to these ligands. In this study, we prepared type B FL-HA; three-
arm HA, dimers of mini-HA; two-arm HA, and monomers of mini-HA; one-arm HA, 
and we investigated the multivalency effects of HA on the epithelial barrier disruption.  
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Materials and Methods 
Plasmid construction  
    The genomic DNA was extracted and purified from C. botulinum type B strain Okra. 
HA1 (aa 7-294) encoding gene was cloned into the KpnI-SalI site of the pET52b(+) 
vector (Novagen, Merck Millipore, Madison, WI, USA), and an oligonucleotide 
encoding a FLAG-tag was inserted at the C-terminus of HA1. HA2 (aa 2-146) encoding 
gene was cloned into the HindIII-KpnI site of pT7-FLAG-1 vector (Sigma Aldrich, St. 
Louis, MO, USA). The full-length HA3 (HA3-FL, aa 19-626) encoding gene was 
cloned into the KpnI-SalI site of the pET52b(+) vector. The truncated mutant of HA3  
(termed HA3-mini, aa 380-626) encoding gene was cloned into the NcoI-SalI site of the 
pET52b(+) vector, and an oligonucleotide encoding a Strep-tag II tag was inserted at the 
C-terminus of HA3-mini. Site-directed mutagenesis was performed using PrimeSTAR 
Max polymerase (Takara Bio, Shiga, Japan). The inserted regions of these plasmids and 
the presence of mutation were confirmed by DNA sequencing.  
Protein expression and purification  
    The expression of HA proteins was conducted using Overnight Express 
Autoinduction System 1 (Novagen, Merck Millipore, Darmstadt, Germany), as 
previously described (25). FLAG-tagged proteins, HA1 with a C-terminal FLAG-tag 
(HA1-FLAG) and HA2 with an N-terminal FLAG-tag (FLAG-HA2), were purified 
using anti-FLAG tag M2 agarose gel beads (Sigma Aldrich, St. Louis, MO, USA). 
Strep-tag II-tagged proteins, HA3-FL with an N-terminal Strep-tag II tag (Strep-HA3-
FL) and HA3-mini with a C-terminal Strep-tag II tag (HA3-mini-Strep), were purified 
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using StrepTrap HP (GE Healthcare, Freiburg, Germany). All proteins were dialyzed 
against PBS (pH 7.4).  
    Recombinant mouse E-cadherin ectodomain 1-5 protein with a hexa-histidine tag at 
the C-terminus (E-cadherin EC1-5-His) was expressed in HEK293 cells, and purified as 
previously described (17).  
In vitro reconstitution and purification of HAs  
    The purified HA1, HA2, and HA3 (HA3-FL for FL-HA, HA3-mini for mini-HA) 
were mixed at a molar ratio of 4:4:1 in PBS and incubated for 3 hr at 37°C. The FL-HA 
and mini-HA complexes were purified using StrepTrap HP. The mini-HA complex was 
subjected to further purification on a Superdex 200 Increase 10/300 GL column (GE 
Healthcare, Uppsala, Sweden) in PBS. Purified proteins were dialyzed against PBS.  
Size-exclusion chromatography analysis of HAs  
    Fifty µg of each purified HA protein was loaded onto a Superdex 200 Increase 10/300 
GL column in PBS. Twenty-five µg of each mini-HA (in a concentration of 2.2 µM as 
protomers) was incubated at 37°C for the indicated time. Then, the mini-HA was loaded 
onto a Superdex 200 Increase 10/300 GL column in PBS. The protein concentration of 
the elution was measured based on absorbance at 280 nm.  
Transepithelial electrical resistance (TER) assay  
    Measurement of TER was performed using Millicell-ERS (Merck Millipore, Billerica, 
MA, USA), as previously described (15). In brief, Caco-2 cells were grown on 24-well 
collagen-coated Transwell filters (Corning, Tewksbury, MA, USA) in Eagle's MEM 
(Gibco, ThermoFisher Scientific, Ghent, Belgium) supplemented with 20% fatal bovine 
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serum (FBS) until completely confluent, and Caco-2 cell monolayers were formed. HAs 
were added to the basolateral side of the monolayers at final concentrations of 51 nM  
of protomer of HAs (17 nM FL-HA; 25.5 nM dimer fraction of mini-HA; 51 nM 
monomer fraction of mini-HA), 102 nM of protomer of a dimer fraction of mini-HA (51 
nM dimer fraction), and 255 nM of protomer of a monomer fraction of mini-HA (255 
nM monomer fraction). TER was measured at time points up to 24 hr post-addition.  
Pull-down assay  
    FL-HAs and mini-HAs (20 pmol of protomer of HAs) were immobilized onto Strep-
Tactin Superflow agarose gel beads (Novagen, Merck Millipore, Darmstadt, Germany) 
by incubation for 1 hr at 4°C in TNCX buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 
2 mM CaCl2, 0.01% Triton X-100). The concentration of E-cadherin ectodomain 
protein was adjusted to 100 nM in TNCX buffer. A 200 µl aliquot of E-cadherin 
solution was subjected to pull-down with beads coupled to FL-HA, a dimer fraction or a 
monomer fraction of mini-HA for 2 hr at 4°C. The beads were washed three times, and 
the bound proteins were eluted in SDS-PAGE sample buffer. Samples were separated 
by 12.5% SDS-PAGE and transferred to a PVDF membrane (Immobilon-P; Merck 
Millipore, Darmstadt, Germany), followed by immunoblotting with rat anti-mouse E-
cadherin monoclonal antibody (ECCD-2; Takara Bio, Shiga, Japan; 1:500). Bound 
antibodies were probed with horseradish-peroxidase (HRP)-conjugated goat anti-rat IgG 
antibody (Jackson ImmunoResearch, West Grove, PA, USA; 1:10000), and the 
membranes were developed using ECL select (Amersham, GE Healthcare, 
Buckinghamshire, UK). After immunoblotting, the membranes were stained with 
Coomassie brilliant blue (CBB) to visualize HA proteins.  
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Sandwich enzyme linked immunosorbent assay (ELISA)  
    Ninety-six-well microtiter plates (IWAKI, Tokyo, Japan) were coated with 100 µl of 
mouse anti-His tag antibody (OGHis; MBL, Nagoya, Japan; 1:1000) in 0.05 M 
carbonate buffer at pH 9.6. Subsequent incubations were carried out for 1 hr at 37°C. 
After washing with TNCT buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 2 mM 
CaCl2, 0.05% Tween-20), plates were blocked with 1% BSA in TNCT buffer. Plates 
were washed and incubated with 100 nM E-cadherin EC1-5-His in the blocking buffer 
(1% BSA in TNCT buffer). Then, plates were washed and incubated with 100 nM of 
protomer of HAs. After washing, plates were incubated with rabbit anti-FLAG tag 
polyclonal antibody (#2368; Cell Signaling Technology, Beverly, MA, USA; 1:1000) in 
the blocking buffer, followed by HRP-conjugated goat anti-rabbit IgG antibody 
(Jackson ImmunoResearch, West Grove, PA, USA; 1:10000). Plates were developed 
using ABTS (Roche Diagnostics, Mannheim, Germany), and the absorbance at 405 nm 
was read.  
Cell-ELISA  
    Caco-2 cells were grown on 24-well collagen-coated Transwell filters until 
completely confluent. HAs were added to the basolateral side at a final concentration of 
51 nM protomer, and the monolayers were incubated in Caco-2 cell culture medium 
(MEM, 20% FBS) for 40 min at 4°C. After washing with ice-cold PBS, the cells on the 
Transwell filters were fixed with 4% paraformaldehyde (PFA) for 30 min at 4°C, 
followed by blocking with 5% BSA in PBS for 30 min at room temperature. Then, the 
basolateral sides of the monolayers were incubated with mouse anti-FLAG tag 
monoclonal antibody (M2; Sigma Aldrich, St. Louis, MO, USA; 1:5000) in the 
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blocking buffer (5% BSA in PBS) for 2 hr at 37°C, followed by HRP-conjugated 
donkey anti-mouse IgG antibody (Jackson ImmunoResearch, West Grove, PA, USA; 
1:10000) for 1 hr at 37°C. The Transwell filters were developed using ABTS, and the 
absorbance at 405 nm was read.  
Immunofluorescence  
    HAs were added to the basolateral side of Caco-2 cells grown on Transwell filters, 
and the monolayers were incubated in the Caco-2 cell culture medium for 40 min at 4°C. 
After fixation with 4% PFA for 30 min at 4°C and permeabilization with 0.5% Triton 
X-100 in PBS for 5 min at room temperature, the cells were blocked with 5% BSA in 
PBS for 30 min at room temperature. Then, HA was stained with a mouse anti-FLAG 
tag (1:1000) monoclonal antibody, followed by Cy3-conjugated donkey anti-mouse IgG 
antibody (Jackson ImmunoResearch, West Grove, PA, USA; 1:400). After 
immunostaining, the Transwell filters were mounted in ProLong antifade reagent 
(Molecular Probes, ThermoFisher Scientific, Eugene, OR, USA). Images were acquired 
by confocal microscopy using a CSUX1 confocal scanner unit (Yokogawa Electric, 
Tokyo, Japan) and IX71 microscope (Olympus, Tokyo, Japan) and processed using 
Metamorph software (Molecular Devices, Sunnyvale, CA, USA).   
Pulse-chase analysis  
    The purified FLAG-HA2 was labeled using Alexa Fluor 568-NHS (Molecular Probes, 
ThermoFisher Scientific, Eugene, OR, USA) following the manufacturer's protocol. 
Alexa-labeled HA complexes were reconstituted from Alexa-labeled FLAG-HA2 and 
non-labeled HA1-FLAG and HA3 (Strep-HA3-FL for FL-HA, HA3-mini-Strep for 
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mini-HA), and purified as described in the In vitro reconstitution and purification of 
HAs section. The SEC profiles of Alexa-labeled HA complexes are consistent with 
those of non-labeled HA complexes (data not shown). Basolateral sides of Caco-2 cells 
grown on collagen-coated 24-well Transwell filters were incubated with 153 nM of 
protomer of Alexa-labeled HA complexes in the Caco-2 cell culture medium for 40 min 
at 4°C. After a brief wash in the ice-cold Caco-2 cell culture medium, the monolayers 
were incubated with 153 nM protomer of non-labeled HA complexes in the Caco-2 cell 
culture medium for the indicated time (10 or 20 min) at 37°C. After pulse or chase 
labeling, the monolayers were fixed and stained with rat anti-E-cadherin (DECMA-1; 
Sigma-Aldrich, St. Louis, MO, USA; 1:1000) and mouse anti-ZO-1 (ZO1-1A12; 
Zymed, ThermoFisher Scientific, Carlsbad, CA, USA; 1:250) monoclonal antibodies, 
followed by Alexa Fluor 488-conjugated goat anti-rat IgG antibody (Molecular Probes, 
ThermoFisher Scientific, Eugene, OR, USA; 1:400) and Alexa Fluor 405-conjugated 
goat anti-mouse IgG antibody (Molecular Probes, ThermoFisher Scientific, Eugene, OR, 
USA; 1:400), respectively. After immunostaining, images were acquired by confocal 
microscopy.     
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Results 
Preparation of one-, two-, and three-arm HAs  
    Full-length HAs (FL-HAs) and mini-HAs of type B were reconstituted in vitro from 
purified HA subcomponents expressed in E. coli (Fig. 2 and Supp. Fig. 1a). We 
constructed the mini-HA of type B, which consists of HA1, HA2, and an HA3 mutant 
deleted N-terminal 379 amino acid (aa) residues, in the same manner as mini-HA of 
type A reported by Lee et al. (24). Reconstituted mini-HA showed two major peaks by 
size-exclusion chromatography (SEC) (Fig. 2a). Among all HA subcomponents, only 
HA3-mini showed the two similar peaks (Supp. Fig. 1a). It is considered that the 
dimerization of mini-HA is due to a weak association between HA3-minis. After SEC 
separation of the two major peaks of mini-HA, the re-run profiles of each fraction on 
SEC showed single major peaks individually at 10.5 ml (dimer, corresponding to two-
arm HA, predicted mass: 232 kDa) and 12.5 ml (monomer, corresponding to one-arm 
HA, predicted mass: 116 kDa) (Fig. 2b). While the height of each minor peak of mini-
HAs was slightly increased after incubation at 37°C for 24 hr in PBS, each major peak 
was mostly retained (Supp. Fig. 1b,c). FL-HA was predominantly eluted at 9.0 ml 
(corresponding to three-arm HA, predicted mass: 474 kDa) in SEC (Fig. 2b).  
Fractionated mini-HAs disrupt the epithelial barrier of Caco-2 cells  
    In polarized epithelial cells, junctional complexes such as tight junctions (TJs), E-
cadherin-based adherence junctions (AJs), and desmosomes are oriented in an apical-to-
basal arrangement (27). Epithelial TJs seal adjacent epithelial cells and regulate the 
paracellular permeability (28). Thus, macromolecules, e.g., HA and PTCs, do not gain 
12 of  34 
direct access to E-cadherin from the apical side of the epithelial cell, suggesting that a 
transcytosis step to the basolateral side is required for apically applied HA to interact 
with E-cadherin (15). To assess the direct barrier-disrupting activities of HAs, we 
measured the transepithelial electrical resistance (TER) of Caco-2 cell monolayers 
following basolateral treatment with HAs (Fig. 3). FL-HA and dimer and monomer 
fractions of mini-HA disrupted the epithelial barrier of Caco-2 cells (Fig. 3). The 
barrier-disrupting activities of dimer and monomer fractions of mini-HA were decreased 
to approximately one-half and one-fifth of that of FL-HA, respectively (Fig. 3). The 
TER value of Caco-2 cells with FL-HA was decreased to 84% at 2 hr post addition, and 
that with the higher concentration of dimer (102 nM as protomer, 2x Dimer) and 
monomer (255 nM, 5x Monomer) fractions of mini-HA was decreased to 54 and 69%, 
respectively (Fig. 3). However, the TER values after 6 hr post addition with mini-HAs 
(2x Dimer. 41~30%; 5x Monomer, 46~41%) was higher than that of FL-HA (37~17%) 
(Fig. 3). 
Binding of HAs to E-cadherin  
    To assess the interaction between HAs and the E-cadherin extracelluar domain, we 
performed pull-down assays and sandwich ELISAs using recombinant E-cadherin EC1-
5-His, which was expressed in HEK293 cells and purified (Fig. 4). In the pull-down 
assay, E-cadherin EC1-5 comparably bound to Strep-tag II tagged FL-HA wild-type 
(WT) and mini-HAs immobilized on Strep-Tactin beads (Fig. 4a). In the sandwich 
ELISA, E-cadherin EC1-5, which contains a hexa-histidine tag at the C-terminus, was 
immobilized to anti-His tag antibody-coated plates, and then HAs were added to these 
plates. As a result, the E-cadherin-binding abilities of dimer and monomer fractions of 
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mini-HA were relatively weak, and 65% and 10% of that of FL-HA WT, respectively 
(Fig. 4b). It has been reported that HA3 Lys607 is located at the interface with E-
cadherin (Fig. 1c), and its alanine substitution (K607A, KA) impairs the E-cadherin-
binding and barrier-disrupting activity (18, 19). FL-HA harboring a KA mutation (FL-
HAKA) did not interact with E-cadherin EC1-5 in these experiments (Fig. 4). 
Attachments of HAs to the basolateral surface of Caco-2 cells  
    We examined the abilities of HAs to attach to the basolateral cell surface by cell-
ELISA using Caco-2 cell monolayers (Fig. 5a). FL-HA WT attached to the basolateral 
cell surface (Fig. 5a). To identify how HA attaches to the basolateral surface of Caco-2 
cells, we performed these experiments using functional mutants of FL-HA. The 
galactose-binding site of HA1 and the sialic acid-binding site of HA3 have already been 
identified in type A, B, and C by co-crystallization with saccharides (Fig. 1c) (24, 29–
31). It has also been reported that alanine substitutions of HA1 Asn286 (N286A, NA) 
and HA3 Arg528 (R528A, RA) abolish each carbohydrate binding (19, 24, 29). FL-HA 
WT attached to the basolateral cell surface (Fig. 5a). FL-HA harboring an NA mutation 
(FL-HANA) rarely attached to the basolateral cell surface (Fig. 5a). The basolateral cell 
surface attachment of FL-HA harboring an RA mutation (FL-HARA) was 70% of that of 
FL-HA WT, and that of FL-HAKA was comparable with that of FL-HA WT (Fig. 5a). 
These results indicate that HA attached to the basolateral surface of Caco-2 cells by 
binding mainly to galactose. The basolateral cell surface attachment of dimer and 
monomer fractions of mini-HA were 20% and 7% of that of FL-HA WT, respectively 
(Fig. 5a). Next, HAs that attached to the basal cell surface were visualized using 
immunofluorescence (Fig. 5b). FL-HA WT, FL-HARA, and FL-HAKA attached to the 
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basal surface of Caco-2 cells homogeneously (Fig. 5b). The FL-HANA attached to the 
cell surface was rarely observed (Fig. 5b). The attachment of the dimer fraction of mini-
HA to the basal cell surface was weaker than FL-HA WT, and the monomer fraction of 
mini-HA showed very weak attachment (Fig. 5b). 
Pulse-chase analysis  
    The z-stacked images showed that basolaterally applied HAs localized only to the 
basal cell surface, and not to the lateral cell surface at 4°C (Fig. 6a). It has been reported 
that basolaterally applied FL-HA WT localized to the basal and lateral surfaces of Caco-
2 cells when incubated continuously at 37°C (17, 19). Therefore, we postulate that HA 
attaching to the basal cell surface moves to the lateral cell surface. To examine this 
hypothesis, we performed pulse-chase experiments (Fig. 6a-c). After chasing for 10 ~ 
20 min at 37°C, some of the FL-HA WT that attached to the basal cell surface moved to 
the lateral cell surface (Fig. 6b,c). In the similar way, the dimer fraction of mini-HA 
moved to the lateral cell surface, albeit at a lower level compared with FL-HA WT. The 
monomer fraction of mini-HA moved to the lateral cell surface only slightly (Fig. 6c). 
FL-HAKA did not localize to the lateral cell surface, and some of the FL-HAKA were 
endocytosed into the cytoplasm (Fig. 6b,c). E-cadherin showed major localization 
throughout the lateral cell surface and infrequent localization to the basal cell surface 
(Fig. 6a,b).  
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Discussion 
    Our results showed that the greater number of arms HA has, the more effectively it 
disrupts the epithelial barrier of human intestinal Caco-2 cell monolayers, that is, the 
barrier-disrupting activity of HA is markedly increased by the multivalency effect of 
HA. Our results also revealed that the three-arm form of HA is not essential for 
epithelial barrier disruption. The monomer fraction of mini-HA slightly compromised 
the integrity of the epithelial barrier, but significantly compromised it at a higher 
concentration (Fig. 3). These results imply that one-arm HA is capable of disrupting the 
epithelial barrier. However, the possibility cannot be excluded that one-arm HA has no 
activity to disrupt the epithelial barrier, and a small amount of two-arm HA existing in 
the monomer fraction causes this activity; there might exist dimers of mini-HA in the 
monomer fraction for some reasons, e.g., contamination of dimers in the fractionation 
procedure, and/or dimerization under the experimental conditions. The barrier-
disrupting activities of mini-HAs are weakened at 4-6 hr post-addition, possibly through 
the instability of mini-HAs because of the truncating mutation. 
    Consistent with the results of Lee, et al. (18), the binding ability to un-immobilized 
E-cadherin was comparable between FL-HA and mini-HAs (Fig. 4a). However, the 
binding ability of HA to immobilized E-cadherin was markedly enhanced by the 
multivalency effect (Fig. 4b). Assuming that the immobilized E-cadherin exists as a 
cluster on the plates, these results suggest that the multivalency effect of HA might 
cause the effective interaction with E-cadherin that resides on the lateral cell surface and 
exists as a cluster. 
    We previously found that the barrier-disrupting activity of FL-HANA was one-fifth of 
that of FL-HA WT, and the activity of FL-HARA was slightly less than that of FL-HA 
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WT, when these HAs were applied from the basolateral side, even though they showed 
the same binding ability to E-cadherin in the pull-down assay (19). Hence, it is 
considered that the carbohydrate-binding activity of HA increases the opportunities to 
meet E-cadherin by promoting the basolateral cell surface attachment, leading to more 
effective barrier disruption (19). Our present results show that HA attaches to the basal 
surface of Caco-2 cells by binding mainly to the terminal galactose residue on 
glycoproteins/glycolipids (Fig. 5 and Fig. 6a). It is well-known that the interaction 
between carbohydrates and lectins could be markedly enhanced by the multivalency 
effects of lectins (32–34). In a similar way, the intermediate L-PTC of type D, which 
has a smaller number of HA1-HA2 complexes than mature L-PTC, attaches to the 
surface of rat intestinal epithelial IEC-6 cells by carbohydrate binding weaker than 
mature L-PTC (35). Consistently, our results revealed that the attachment of HA to the 
basolateral surface of Caco-2 cells is markedly enhanced by the multivalency effect of 
HA (Fig. 5).  
    Pulse-chase experiments revealed that basolaterally applied HAs initially attach only 
to the basal surface of Caco-2 cells, and then the bound HAs move to the lateral cell 
surface (Fig. 6a-c). FL-HAKA, which does not interact with E-cadherin, was able to 
attach to the basal cell surface as well as FL-HA WT (Figs. 5 and Fig. 6a). However, 
FL-HAKA did not move to the lateral cell surface after chasing (Fig. 6b,c). These results 
suggest that this movement of HA is dictated by E-cadherin. It is known that cadherin 
molecules flow within the lateral plasma membrane in a basal-to-apical direction and 
this flow is called “cadherin flow” (36, 37). Therefore, it is assumed that HA binds to E-
cadherin at the basal cell surface and then rides on cadherin flow. This movement of HA 
was increased by the multivalency effect of HA (Fig. 6c). We previously reported that 
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the amount of the carbohydrate-binding defective mutant FL-HA (FL-HANA/RA, FL-HA 
harboring both NA and RA) located at the lateral cell surface is much lower than that of 
FL-HA WT, when these HAs are applied basolaterally and the monolayers are 
incubated continuously at 37°C (19). These observations indicate that the movement of 
HA from the basal to lateral cell surface is promoted by the basal cell surface 
attachment via carbohydrate residues, which consequently increases the opportunities to 
meet E-cadherin, and this attachment step is enhanced by the multivalency effect of HA. 
    Recently, we reported that L-PTC of type A enters the host through M cells via GPI-
anchored glycoproteins-mediated transcytosis. Binding to these glycoproteins is 
responsible for HA in a carbohydrate-binding-dependent manner (13). Therefore, it is 
assumed that the multivalency effect of HA enhances the attachment of L-PTC to the 
luminal surface of M-cells and increaces the efficiency of transcytosis across the 
intestinal lumen. 
    In conclusion, we revealed that basolaterally applied HA initially binds to 
glycoproteins/glycolipids only at the basal cell surface and then moves to the lateral cell 
surface, where HA acts to disrupt the epithelial barrier. Our results show that the 
multivalency effect of HA increases the epithelial barrier-disrupting activity, and this 
phenomenon is considered to be induced by at least two mechanisms: enhancing the cell 
surface attachment via carbohydrate residues at the basal cell surface, and enhancing the 
binding avidity to clustered E-cadherin that resides on the lateral cell surface. 
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Figure Legends 
Figure 1. Molecular composition of full length-HA (FL-HA) and mini-HA.  
(a) Reconstituted L-PTC (left panel) and protomer of HA (right panel) are represented 
by mesh and cartoon style (EMBD ID: 3724, PDB ID: 3V0A and 3WIN) (7, 24, 25). 
The figures were generated by PyMOL (38) and UCSF Chimera (39) (b) Schematic 
models of FL-HA and mini-HA. FL-HA is composed of HA1, HA2, and full-length 
HA3 (HA3-FL; aa 19-626) and mini-HA is composed of HA1, HA2, and HA3-mini (aa 
380-626). N-terminal deletion of HA3-FL was introduced based on N-terminal 
sequencing of HA proteins produced by C. botulinum (5). (c) A part of FL-HA and 
mini-HA are represented by surface and ribbon style, respectively. N286 of HA1 (red), 
R528 (blue) and K607 (black) of HA3 are represented by sphere style and indicated by 
labeled arrows. 
Figure 2. Size-exclusion chromatography. 
(a) The reconstituted and purified mini-HA was subjected to size-exclusion 
chromatography (SEC), and fractions in green- and red-filled areas were collected 
as dimers and monomers, respectively. Arrows show dimer and monomer peaks. 
(b) FL-HA (blue), a dimer fraction of mini-HA (D, green) and a monomer fraction 
of mini-HA (M, red) were subjected to SEC. The retention volumes of standard 
proteins are indicated above with their molecular weight.  
Figure 3. Transepithelial resistance assay with Caco-2 cells. 
Caco-2 cells grown on Transwell chambers were treated with 51 nM of protomer of 
HAs (17 nM FL-HA, blue line; 25.5 nM dimer fraction mini-HA, green line; 51 nM 
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monomer fraction of mini-HA, red line), 102 nM of protomer of dimer fraction of 
mini-HA (2x, green dash) and 255 nM of monomer fraction of mini-HA (5x, red 
dash), from the basolateral side. TER was measured up to 24 hr post-addition. 
Values are means ± S.E. of triplicate wells.   
Figure 4. Interaction between HAs and E-cadherin. 
Direct interactions between HAs and un-immobilized/immobilized E-cadherin 
EC1-5-His, which was expressed in HEK293 cells and purified, are shown by pull-
down assay (a) and sandwich ELISA (b), respectively. (a) The pull-down samples 
were detected by Western blotting analysis with an ECCD-2 antibody against E-
cadherin. HA proteins on a PVDF membrane were stained with Coomassie brilliant 
blue (CBB). (b) E-cadherin EC1-5-His was captured on an anti-His tag antibody-
coated plate. Then, HAs were added to the plate and the bound HAs were detected 
by ELISA with polyclonal antibody against FLAG-tag. Values are means ± S.E. of 
triplicate wells. **P < 0.01; by unpaired, two-tailed t-test.   
Figure 5. Attachment of HAs to the basolateral surface of Caco-2 cells. 
(a) 51 nM of protomer of HAs was added to the basolateral side of Caco-2 cells 
grown in Transwell chambers, and monolayers were incubated for 40 min at 4°C. 
After fixation with 4% PFA, HAs that attached to the basolateral cell surface were 
detected by cell-ELISA with M2 antibody against FLAG tag. Values are means ± 
S.E. of triplicate wells. ns: not significant; *P < 0.05, **P < 0.01; by unpaired, two-
tailed t-test. (b) Confocal microscopy visualization of HAs that attached to the 
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basal surface of Caco-2 cells. Monolayers were stained with M2 antibody against 
FLAG tag.  
Figure 6. Pulse-chase analysis with HA-Alexa568. 
(a-c) After Caco-2 cells grown in the Transwell chamber were incubated with 153 
nM of protomer of Alexa568-labeled HAs (red) from the basolateral side for 40 
min at 4°C (a), the cells were further incubated with 153 nM of protomer of non-
labeled HAs from the same side at 37°C for 10 min (b) or 20 min (c). Monolayers 
were stained with DECMA-1 antibody against E-cadherin (green) and ZO1-1A12 
antibody against ZO-1 (blue). Images were acquired in the x-z plane (a, b) and x-y 
plane at the middle of the cell height (c). Scale bars: 5 µm (a, b) or 10 µm (c).  
Supplemental Figure 1. Size-exclusion chromatography of HA proteins. 
(a) The purified HA subcomponent protein was subjected to SEC. The retention 
volumes of standard proteins are indicated above with their molecular weight. The 
peaks with a single asterisk showed no protein band on SDS-PAGE. (b, c) After 
incubation at 37°C for 0 hr (deep purple), 6 hr (light blue), and 24 hr (light green), a 
dimer fraction (b) and a monomer fraction (c) of mini-HA were subjected to SEC. 
The peaks with double asterisks contain HA1 and HA2. 
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